You are about to be redirected to a site intended for people with primary HLH or their caregivers.
You are being redirected to a third party website.
Sobi takes no responsibility for the content of this website.
For patients with refractory, recurrent, or progressive disease or intolerance to conventional HLH therapy.
(95% CI: 0.42, 0.81; P = 0.013)
Gamifant was shown to neutralize IFNγ as measured by a rapid and sustained reduction in the plasma concentrations of CXCL9, a chemokine induced almost exclusively by IFNγ. This is consistent with the early onset of clinical action and time to response seen with Gamifant.See how Gamifant works
Primary hemophagocytic lymphohistiocytosis (HLH) is a rare hyperinflammatory condition that mostly affects children, but can also occur in adults and teenagers.3-6
Gamifant reduces the inflammatory symptoms of primary HLH by neutralizing IFNγ.1
Gamifant is given as an intravenous infusion twice per week until the patient no longer requires therapy for the treatment of HLH or until hematopoietic stem cell transplantation (HSCT) is performed.1
Download the Start Form now or contact Gamifant Patient Services at 833-597-6530.